ATE169959T1 - Anthrax-toxin-fusionsproteine und deren verwendungen - Google Patents

Anthrax-toxin-fusionsproteine und deren verwendungen

Info

Publication number
ATE169959T1
ATE169959T1 AT94911385T AT94911385T ATE169959T1 AT E169959 T1 ATE169959 T1 AT E169959T1 AT 94911385 T AT94911385 T AT 94911385T AT 94911385 T AT94911385 T AT 94911385T AT E169959 T1 ATE169959 T1 AT E169959T1
Authority
AT
Austria
Prior art keywords
protein
domain
cell
native
binding domain
Prior art date
Application number
AT94911385T
Other languages
English (en)
Inventor
Stephen H Leppla
Kurt Klimpel
Naveen Arora
Yogendra Singh
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/021,601 external-priority patent/US5591631A/en
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE169959T1 publication Critical patent/ATE169959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94911385T 1993-02-12 1994-02-14 Anthrax-toxin-fusionsproteine und deren verwendungen ATE169959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/021,601 US5591631A (en) 1993-02-12 1993-02-12 Anthrax toxin fusion proteins, nucleic acid encoding same
US08/082,849 US5677274A (en) 1993-02-12 1993-06-25 Anthrax toxin fusion proteins and related methods

Publications (1)

Publication Number Publication Date
ATE169959T1 true ATE169959T1 (de) 1998-09-15

Family

ID=26694882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911385T ATE169959T1 (de) 1993-02-12 1994-02-14 Anthrax-toxin-fusionsproteine und deren verwendungen

Country Status (8)

Country Link
US (1) US5677274A (de)
EP (1) EP0684997B1 (de)
AT (1) ATE169959T1 (de)
AU (1) AU682500B2 (de)
CA (1) CA2155514A1 (de)
DE (1) DE69412593T2 (de)
ES (1) ES2122257T3 (de)
WO (1) WO1994018332A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5132996A (en) * 1995-03-01 1996-09-18 Alexander Varshavsky Codominance-mediated toxins
EP0909322B1 (de) * 1996-04-30 2005-11-16 Twinstrand Therapeutics Inc. Antivirale variante von ricin-proteinen
US6592872B1 (en) * 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US7247715B2 (en) 1997-04-30 2007-07-24 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
AU7023798A (en) * 1997-04-30 1998-11-24 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
WO2001025267A2 (en) 1999-10-04 2001-04-12 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
AU752833B2 (en) * 1998-04-01 2002-10-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Anthrax lethal factor is a MAPK kinase protease
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
AU6906100A (en) * 1999-08-16 2001-03-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
AU771632B2 (en) * 1999-09-24 2004-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
EP1244687A4 (de) * 1999-12-22 2005-06-15 Univ Ohio State Res Found Schutzma nahmen gegen die tödliche infektion durch i bacillus anthracis
AU2001238501A1 (en) * 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
EP1278764A4 (de) * 2000-05-04 2004-05-19 Harvard College Verbindungen und methoden zur behandlung und vorbeugung bakterieller infektionen(14.11.01)
GB0016702D0 (en) * 2000-07-08 2000-08-23 Secr Defence Brit Expression system
EP1365796A2 (de) 2000-09-01 2003-12-03 Van Andel Institute Hemmung des mitogenaktivierten proteinkinase (mapk)-weges: eine selektive therapeutische strategie gegen melanome
DE10058379A1 (de) * 2000-11-24 2002-06-06 Biotecon Diagnostics Gmbh Neuer Hefestamm für den Verzehr
WO2002046228A2 (en) 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
CN101694497B (zh) * 2001-03-28 2014-11-26 哈佛大学校长及研究员协会 将外源蛋白递送到胞质溶胶中的方法，及其用途
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
EP1420820A4 (de) * 2001-07-31 2005-04-06 Univ Texas Antigene von und antikörper gegen translozierte moleküle von mikroorganismen und ihre verwendungszwecke
DE10139492B4 (de) * 2001-08-13 2004-06-09 Eul, Joachim, Dr. Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA
JP4319908B2 (ja) * 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
US20050123476A1 (en) * 2001-09-05 2005-06-09 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
UA80809C2 (en) * 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7763451B2 (en) 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines
US20040009178A1 (en) * 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
US20040136975A1 (en) * 2002-03-22 2004-07-15 Duesbery Nicholas S Anthrax lethal factor inhibits tumor growth and angiogenesis
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
KR100701811B1 (ko) * 2002-05-29 2007-04-02 머크 앤드 캄파니 인코포레이티드 탄저병의 치료 및 치사 인자의 억제에 유용한 화합물
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
WO2004032839A2 (en) * 2002-10-04 2004-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and formulations comprising agonists and antagonists of nuclear hormone receptors
EP1572977B1 (de) 2002-11-15 2010-03-03 Gen-Probe Incorporated Test und zusammensetzungen zum nachweis von bacillus-anthracis-nukleinsäure
WO2004099254A2 (en) * 2003-05-06 2004-11-18 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US7928290B2 (en) * 2004-02-27 2011-04-19 Dow Agrosciences Llc Viral capsid fusion peptide expressing plant cells
AU2005250351A1 (en) * 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
WO2006091233A2 (en) * 2004-07-23 2006-08-31 Boston Medical Center Corporation Cellular delivery of reagents that inhibit gene expression utilizing the anthrax toxin protective antigen (pa)
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
EP1954307A4 (de) 2005-11-14 2009-12-02 Univ Maryland Biotech Inst Orale impfstoffe gegen milzbrand auf salmonellenbasis
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
WO2008115198A2 (en) 2006-06-30 2008-09-25 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates,synthesis and uses thereof
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US7935345B2 (en) 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
WO2010144794A1 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof
WO2010144799A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Methods and compositions for diagnostic assays for measuring cell mediated immune response
CN102573883A (zh) 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
RU2486524C1 (ru) * 2011-11-09 2013-06-27 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ определения летального фактора сибирской язвы на основе иммунодетекции, сопряженной с полимеразной цепной реакцией
CA2865243A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2013177231A1 (en) * 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437499A1 (fr) 1978-09-27 1980-04-25 Snecma Perfectionnement aux tuyeres orientables pour propulseurs a reaction

Also Published As

Publication number Publication date
EP0684997B1 (de) 1998-08-19
DE69412593T2 (de) 1999-02-18
WO1994018332A2 (en) 1994-08-18
EP0684997A1 (de) 1995-12-06
AU682500B2 (en) 1997-10-09
ES2122257T3 (es) 1998-12-16
AU6392294A (en) 1994-08-29
DE69412593D1 (de) 1998-09-24
CA2155514A1 (en) 1994-08-18
WO1994018332A3 (en) 1994-10-13
US5677274A (en) 1997-10-14

Similar Documents

Publication Publication Date Title
ATE169959T1 (de) Anthrax-toxin-fusionsproteine und deren verwendungen
Germino et al. Rapid purification of a cloned gene product by genetic fusion and site-specific proteolysis.
US5668255A (en) Hybrid molecules having translocation region and cell-binding region
KR950000300B1 (ko) 융합 단백질의 제조방법
AR062867A2 (es) Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la
JPH07503368A (ja) 新規な生物活性ポリペプチド類，ならびにそれらの製造および含有薬学組成物
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
WO1996040915A3 (en) Novel ctla4/cd28 ligands and uses therefor
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
JP3311346B2 (ja) 改良されたキメラ毒素
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
Claeys et al. Multiple gene duplication in the evolution of plasminogen. Five regions of sequence homology with the two internally homologous structures in prothrombin
IE58935B1 (en) Fusion proteins with a eukaryotic ballast portion
RU93045577A (ru) Слитные полипептиды
JP2002536018A5 (de)
Sharma On the recovery of genetically engineered proteins from Escherichia coli
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
Kjeldsen et al. Synthetic Leaders with Potential BiP Binding Mediate High-Yield Secretion of Correctly Folded Insulin Precursors fromSaccharomyces cerevisiae
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
Waxman et al. Primary structure of the COOH-terminal membranous segment of a penicillin-sensitive enzyme purified from two Bacilli.
EP0528686B8 (de) Verfahren zur Herstellung von Peptiden
KR960014346A (ko) 개선된 피브린용해 특성 및 트롬빈-억제 활성을 갖는 이작용성 유로키나제 변이체
JPH02502825A (ja) 好中球活性化因子
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee